---
title: "Insights into Anika Therapeutics Q4 Earnings"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/277037549.md"
description: "Anika Therapeutics (NASDAQ:ANIK) reported its Q4 earnings on February 26, 2026, beating estimates by 616.67% with an EPS of $0.31 compared to an estimate of $-0.06. Revenue increased by $13,000 year-over-year. In the previous quarter, the company also exceeded EPS estimates, resulting in a 1.02% drop in share price the following day. Past performance shows fluctuations in EPS and revenue across recent quarters."
datetime: "2026-02-26T12:08:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277037549.md)
  - [en](https://longbridge.com/en/news/277037549.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277037549.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/277037549.md) | [繁體中文](https://longbridge.com/zh-HK/news/277037549.md)


# Insights into Anika Therapeutics Q4 Earnings

**Anika Therapeutics** (NASDAQ:ANIK) announced its Q4 earnings on Thursday, February 26, 2026 at 07:05 AM.

Here's a breakdown of the earnings report.

### Earnings

Anika Therapeutics beat estimated earnings by 616.67%, reporting an EPS of $0.31 versus an estimate of $-0.06.

Revenue was up $13 thousand from the same period last year.

### Overview of Past Earnings

During the previous quarter, the company beat on EPS by $0.1, leading to a 1.02% drop share price change the next day.

Here's a look at Anika Therapeutics's past performance:

**Quarter**

**Q3 2025**

**Q2 2025**

**Q1 2025**

**Q4 2024**

**EPS Estimate**

\-0.06

\-0.21

0.09

0.09

**EPS Actual**

0.04

\-0.13

\-0.06

\-0.03

**Revenue Estimate**

27.80M

27.04M

28.07M

29.00M

**Revenue Actual**

27.80M

28.22M

26.20M

30.60M

To track all earnings releases for Anika Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### 相关股票

- [Anika Therap (ANIK.US)](https://longbridge.com/zh-CN/quote/ANIK.US.md)

## 相关资讯与研究

- [Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ANIK Stock News](https://longbridge.com/zh-CN/news/281661869.md)
- [Anika Therapeutics Names Steve Griffin CEO as Cheryl Blanchard Becomes Executive Chair](https://longbridge.com/zh-CN/news/271927688.md)
- [Nomadar Secures $2M in 2026 Revenue, More Than Doubling 2025 | NOMA Stock News](https://longbridge.com/zh-CN/news/281242113.md)
- [KDDI's Special Probe Finds 2 Employees at Subsidaries Faked Revenue by 246.1 Billion Yen](https://longbridge.com/zh-CN/news/281184111.md)
- [Caleres’ Licensing Risk: Partner Performance, Brand Dilution, and Revenue Disruption Challenges](https://longbridge.com/zh-CN/news/281674788.md)